TY - JOUR AU - Patard, J. -. J. AU - Leray, E. AU - Rioux-Leclercq, N. PY - 2005 DA - 2005// TI - Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.07.055 DO - 10.1200/JCO.2005.07.055 ID - Patard2005 ER - TY - JOUR AU - Moch, H. AU - Cubilla, A. L. AU - Humphrey, P. A. AU - Reuter, V. E. AU - Ulbright, T. M. PY - 2016 DA - 2016// TI - The 2016 WHO classification of tumours of the urinary system and male genital organs-part a: renal, penile, and testicular tumours JO - Eur Urol VL - 70 UR - https://doi.org/10.1016/j.eururo.2016.02.029 DO - 10.1016/j.eururo.2016.02.029 ID - Moch2016 ER - TY - STD TI - Giles RH, Choueiri TK, Heng DY, et al. Recommendations for the management of rare kidney cancers. Eur Urol. 2017; https://doi.org/10.1016/j.eururo.2017.06.040. ID - ref3 ER - TY - JOUR AU - Vera-Badillo, F. E. AU - Templeton, A. J. AU - Duran, I. PY - 2015 DA - 2015// TI - Systemic therapy for non-clear cell renal cell carcinomas: a systematic review and meta-analysis JO - Eur Urol VL - 67 UR - https://doi.org/10.1016/j.eururo.2014.05.010 DO - 10.1016/j.eururo.2014.05.010 ID - Vera-Badillo2015 ER - TY - JOUR AU - Tannir, N. M. AU - Jonasch, E. AU - Albiges, L. PY - 2016 DA - 2016// TI - Everolimus versus sunitinib prospective evaluation in metastatic non-clear cell renal cell carcinoma (ESPN): a randomized multicenter phase 2 trial JO - Eur Urol VL - 69 UR - https://doi.org/10.1016/j.eururo.2015.10.049 DO - 10.1016/j.eururo.2015.10.049 ID - Tannir2016 ER - TY - JOUR AU - Armstrong, A. J. AU - Halabi, S. AU - Eisen, T. PY - 2016 DA - 2016// TI - Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial JO - Lancet Oncol VL - 17 UR - https://doi.org/10.1016/S1470-2045(15)00515-X DO - 10.1016/S1470-2045(15)00515-X ID - Armstrong2016 ER - TY - JOUR AU - Zisman, A. AU - Chao, D. H. AU - Pantuck, A. J. PY - 2002 DA - 2002// TI - Unclassified renal cell carcinoma: clinical features and prognostic impact of a new histological subtype JO - J Urol VL - 168 UR - https://doi.org/10.1016/S0022-5347(05)64549-1 DO - 10.1016/S0022-5347(05)64549-1 ID - Zisman2002 ER - TY - JOUR AU - Karakiewicz, P. I. AU - Hutterer, G. C. AU - Trinh, Q. -. D. PY - 2007 DA - 2007// TI - Unclassified renal cell carcinoma: an analysis of 85 cases JO - BJU Int VL - 100 UR - https://doi.org/10.1111/j.1464-410X.2007.07148.x DO - 10.1111/j.1464-410X.2007.07148.x ID - Karakiewicz2007 ER - TY - JOUR AU - Seo, A. N. AU - Yoon, G. AU - Ro, J. Y. PY - 2017 DA - 2017// TI - Clinicopathologic and molecular pathology of collecting duct carcinoma and related renal cell carcinomas JO - Adv Anat Pathol VL - 24 ID - Seo2017 ER - TY - JOUR AU - Kuthi, L. AU - Jenei, A. AU - Hajdu, A. PY - 2017 DA - 2017// TI - Prognostic factors for renal cell carcinoma subtypes diagnosed according to the 2016 WHO renal tumor classification: a study involving 928 patients JO - Pathol Oncol Res VL - 23 UR - https://doi.org/10.1007/s12253-016-0179-x DO - 10.1007/s12253-016-0179-x ID - Kuthi2017 ER - TY - JOUR AU - Malouf, G. G. AU - Joseph, R. W. AU - Shah, A. Y. PY - 2017 DA - 2017// TI - Non-clear cell renal cell carcinomas: biological insights and therapeutic challenges and opportunities JO - Clin Adv Hematol Oncol VL - 15 ID - Malouf2017 ER - TY - JOUR AU - Koshkin, V. S. AU - Rini, B. I. PY - 2016 DA - 2016// TI - Emerging therapeutics in refractory renal cell carcinoma JO - Expert Opin Pharmacother VL - 17 UR - https://doi.org/10.1080/14656566.2016.1182987 DO - 10.1080/14656566.2016.1182987 ID - Koshkin2016 ER - TY - JOUR AU - Ornstein, M. C. AU - Rini, B. I. PY - 2016 DA - 2016// TI - The safety and efficacy of nivolumab for the treatment of advanced renal cell carcinoma JO - Expert Rev Anticancer Ther VL - 16 UR - https://doi.org/10.1080/14737140.2016.1184980 DO - 10.1080/14737140.2016.1184980 ID - Ornstein2016 ER - TY - JOUR AU - Motzer, R. J. AU - Escudier, B. AU - McDermott, D. F. PY - 2015 DA - 2015// TI - Nivolumab versus everolimus in advanced renal-cell carcinoma JO - N Engl J Med VL - 373 UR - https://doi.org/10.1056/NEJMoa1510665 DO - 10.1056/NEJMoa1510665 ID - Motzer2015 ER - TY - JOUR AU - Motzer, R. J. AU - Bacik, J. AU - Schwartz, L. H. PY - 2004 DA - 2004// TI - Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma JO - J Clin Oncol Off J Am Soc Clin Oncol VL - 22 UR - https://doi.org/10.1200/JCO.2004.06.132 DO - 10.1200/JCO.2004.06.132 ID - Motzer2004 ER - TY - JOUR AU - Ko, J. J. AU - Xie, W. AU - Kroeger, N. PY - 2015 DA - 2015// TI - The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study JO - Lancet Oncol VL - 16 UR - https://doi.org/10.1016/S1470-2045(14)71222-7 DO - 10.1016/S1470-2045(14)71222-7 ID - Ko2015 ER - TY - STD TI - Moreira RB, McKay RR, Xie W, et al. Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC). J Clin Oncol. 2017;35:482–2. ID - ref17 ER - TY - JOUR AU - Choueiri, T. K. AU - Fay, A. P. AU - Gray, K. P. PY - 2014 DA - 2014// TI - PD-L1 expression in nonclear-cell renal cell carcinoma JO - Ann Oncol Off J Eur Soc Med Oncol VL - 25 UR - https://doi.org/10.1093/annonc/mdu445 DO - 10.1093/annonc/mdu445 ID - Choueiri2014 ER - TY - JOUR AU - Joseph, R. W. AU - Millis, S. Z. AU - Carballido, E. M. PY - 2015 DA - 2015// TI - PD-1 and PD-L1 expression in renal cell carcinoma with Sarcomatoid differentiation JO - Cancer Immunol Res VL - 3 UR - https://doi.org/10.1158/2326-6066.CIR-15-0150 DO - 10.1158/2326-6066.CIR-15-0150 ID - Joseph2015 ER - TY - STD TI - Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427). Available from: https://clinicaltrials.gov/ct2/show/NCT02853344. Accessed 20 Jan 2018. UR - https://clinicaltrials.gov/ct2/show/NCT02853344 ID - ref20 ER -